Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, the FDA issued a warning letter to Grupo Insoma, S.A.P.I de CV, a pharmaceutical company, on October 23, 2020. Without access to the full letter text or subject line details, the specific nature of the drug manufacturing or distribution violations cannot be determined from the available information. The warning falls under FDA's drug product regulatory authority, though the issuing office is not specified in the metadata provided. This letter indicates the company failed to meet applicable FDA requirements for drug products, though the particular compliance deficiencies require review of the complete correspondence.